Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has shared an announcement.
SSY Group Limited has secured production and registration approval in China for its Diltiazem Hydrochloride for Injection (10mg), classified as a type 4 chemical drug and deemed to have passed consistency evaluation. The product targets supraventricular tachycardia, perioperative hypertensive crises, hypertensive emergencies and unstable angina, reinforcing the group’s presence in acute cardiovascular care.
The company has also received approval for Propranolol Hydrochloride Injection in two dosage formats, recognized as a type 3 drug with passed consistency evaluation, following earlier registration approval for its bulk drug. These new approvals broaden SSY Group’s cardiovascular injectable portfolio, enhancing its competitive position in China’s hospital drug market and signaling continued progress in product development that may support future revenue growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a pharmaceutical company based in Hong Kong that develops and manufactures injectable drugs for the hospital and clinical markets. The group focuses on regulated prescription medicines in China, targeting cardiovascular and other critical care indications where high-quality, NMPA-approved injectable formulations are in demand.
YTD Price Performance: -14.13%
Average Trading Volume: 9,304,684
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.17B
See more data about 2005 stock on TipRanks’ Stock Analysis page.